What is ZOMDF's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.09B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ZOMDF?

P/E (TTM) is n/a and 52-week range is $0.06 to $0.16 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ZOMDF figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ZOMDF?

The company profile lists revenue (TTM) near $37M, net income (TTM) near $-1.89B, EPS (TTM) near $-0.02 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Zomedica Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in Ann Arbor, Michigan, US, 980M shares outstanding, ISIN CA98980M1095 when available from company profile and filing metadata.

Zomedica Corp

$ZOMDF

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$0.08

-6.14%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Zomedica Corp. engages in the discovery, development, and commercialization of pharmaceuticals for companion animals, including dogs, cats, and horses. The company is headquartered in Ann Arbor, Michigan and currently employs 141 full-time employees. The company went IPO on 2013-10-28. The firm is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The firm's product portfolio includes diagnostics and medical devices that emphasize patient health and practice economics. Its Diagnostics segment consists of TRUFORMA, VETGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi Loop and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field therapy.

Employees

141

Website

zomedica.com/

IPO

2013-10-28

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)